Compare ADMA Biologics Inc (ADMA) vs iShares MSCI Australia ETF (EWA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs iShares MSCI Australia ETF — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while iShares MSCI Australia ETF trades at $29.94. The key difference: iShares MSCI Australia ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | EWA | |
|---|---|---|
Market Cap | $2.18B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $20.38 | $30.41 |
52-Week Low | $7.60 | $24.95 |
Enterprise Value | $2.25B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
EWA trades at $30.41, up 0.83% with a bullish technical bias from moving averages, though oscillators signal caution with RSI levels above 70 indicating potential overbought conditions. The stock shows strong momentum with ADX readings above 36, while support and resistance cluster near $30-$31. Recent corporate actions include a scheduled dividend of $0.40 per share for June 2026.
Outlook remains positive given technical strength, but elevated RSI warrants monitoring for pullbacks. Risks include macroeconomic sensitivity and sector competition. Investment appeal hinges on sustained earnings growth and dividend stability, with current levels offering limited upside near resistance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →
